BioGaia AB Series B | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
234,351.00
210,679.00
226,895.00
243,082.00
310,856.00
289,794
Total Accounts Receivable
72,050.00
98,592.00
89,688.00
98,558.00
105,251.00
154,819
Inventories
14,585.00
21,148.00
43,546.00
40,479.00
32,612.00
44,213
Other Current Assets
2,130.00
2,342.00
4,932.00
1,314.00
1,035.00
5,589
Total Current Assets
323,116.00
332,761.00
365,061.00
383,433.00
449,754.00
494,415
Net Property, Plant & Equipment
60,286.00
72,752.00
83,934.00
82,430.00
102,465.00
105,935
Total Investments and Advances
-
4,000.00
7,936.00
10,752.00
9,932.00
-
Intangible Assets
-
6,075.00
16,225.00
-
-
51,150
Other Assets
17.00
20.00
22.00
1,930.00
4,622.00
43
Total Assets
383,419.00
415,608.00
473,178.00
488,978.00
576,112.00
659,973
Accounts Payable
17,808.00
16,952.00
23,638.00
16,951.00
20,893.00
Income Tax Payable
29,340.00
7,105.00
-
94.00
6,307.00
Other Current Liabilities
19,329.00
46,768.00
53,356.00
56,421.00
84,246.00
Total Current Liabilities
66,477.00
70,825.00
76,994.00
73,466.00
111,446.00
Deferred Taxes
85.00
192.00
351.00
10,101.00
8,561.00
Total Liabilities
66,562.00
71,017.00
77,345.00
73,798.00
112,224.00
Common Equity (Total)
317,341.00
344,492.00
395,851.00
415,198.00
463,904.00
Total Shareholders' Equity
317,341.00
344,492.00
395,851.00
415,198.00
463,904.00
Total Equity
316,857.00
344,591.00
395,833.00
415,180.00
463,888.00
Liabilities & Shareholders' Equity
383,419.00
415,608.00
473,178.00
488,978.00
576,112.00
Accumulated Minority Interest
484.00
99.00
18.00
18.00
16.00

About BioGaia AB

View Profile
Address
Kungsbroplan 3
Stockholm AB 112 27
Sweden
Employees -
Website http://www.biogaia.com
Updated 07/08/2019
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment is comprised of sales of drops, oral rehydration solutions (ORS), digestive health tablets and also cultures as an ingredient in a licensee's products, as well as royalties pertaining to pediatric products.